Fda Clears Breast Cancer Vaccine For Clinical Trials
Triple-negative breast cancer—so named because it does not produce receptors for the hormones estrogen and progesterone and only produces HER2, the receptor for the protein human epidermal growth factor, in small amounts—accounts for about 10-15% of all breast cancers, making it one of the disease’s rarer incarnations. The vaccine, Tuohy tells Verywell, essentially works by nipping tumor development in the bud. By imbuing immune cells with the ability to recognize, attack, and kill cancer cells, it prevents them from ever reaching a size at which they could inflict lethal damage on the body....